US OptionsDetailed Quotes
ACIU250117C2500
- 0.00
- 0.000.00%
15min DelayClose Dec 27 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV-8.42%PremiumJan 17, 2025Expiry Date0.23Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma4.55Leverage Ratio--Theta--Rho--Eff Leverage--Vega
AC Immune Stock Discussion
AC Immune SA - ACI-24.060 Safe and Well Tolerated in Down Syndrome Patients
AC Immune Reports Positive Interim Results From Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
AC Immune (NASDAQ: ACIU) announced positive interim results from its Phase 2 VacSYn trial of ACI-7104.056, an active immunotherapy for early Parkinson's disease.
The treatment showed significant efficacy, inducing anti-a-synuclein antibody levels 16-fold higherthan placebo after 3 immunizations, with a 100% patient response rate.
The trial rep...
AC Immune Reaches Key Milestone in Alzheimer's Immunotherapy, Receives CHF 24.6M
Benzinga· 10 mins ago5mins
AC Immune (ACIU.US)
3.270
3.530
+2.83%
+7.95%
AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that it will receive the second ReTain-related milestone payment (CHF 24.6 million) under its agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson co...
Dow Jones· 7 mins ago
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
AC Immune SA (NASDAQ: ACIU) has received a second milestone payment of CHF 24.6 million from Janssen Pharmaceuticals for the rapid prescreening rate in the Phase 2b ReTain trial of ACI-35.030 (JNJ-2056) for preclinical Alzheimer's disease. This brings the total milestone payments for this trial to CHF 40 million. The potentially regist...
AC Immune Gets FDA Fast-Track Designation for Neurodegenerative Diagnostic Scan
AC Immune's partner, Life Molecular Imaging (LMI), has received Fast Track Designation from the FDA for the Tau-PET diagnostic [18F]PI-2620 in three neurodegenerative conditions: Alzheimer's disease (AD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). PI-2620, currently in Phase 3 clinical development for detecting Tau pathology in AD, is a next-generation PET imag...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
AC Immune SA (NASDAQ: ACIU) will present three oral presentations at the Alzheimer's Association International Conference (AAIC 2024) in Philadelphia, showcasing its precision medicine pipeline for neurodegenerative diseases. The presentations will focus on:
1. [18F]ACI-19626, a first-in-class TDP-43-PET tracer
2. ACI-24.060, an...
No comment yet